Metoprolol in Chronic Obstructive Pulmonary Disease without Cardiovascular Disease.

Authors

Josefin Sundh, Anders Magnuson, Marika Kvarnström, Folke Sjöberg, Magnus Ekström, Johan SanMartin Berglund, David Ellingsen, Daniel Wilhelms, Mikael Hasselgren, Sara Fristorp Cesarini, Katarina Berndtsson Blom, Anders Blomberg, Lowie E G W Vanfleteren, Andreas Palm, Carolina Smith, Lina Renström, Jens Ellingsen, Christer Janson, Martin Lundvall, Florim Delijaj, Elsa Norberg, Beatrice Larsson, Taivo Kipper, Zaky Chowdhury, Emily Jensen, Henning Stenberg, Maria Hårdstedt, Zainab Ahmadi, Kaveh Azizi, Wolfgang Greger, Scott Montgomery, Ole Fröbert

Published in

NEJM evidence. Pages EVIDoa2600231. Sep 06, 2026. Epub Sep 06, 2026.

Abstract

Beta-blockers may improve outcomes in patients with chronic obstructive pulmonary disease (COPD) without cardiovascular disease, but randomized trials have been inconclusive.
This was a multicenter, open-label, pragmatic, phase 4 randomized trial. Patients 40 years of age or older with COPD, sinus rhythm, and no cardiovascular disease were randomly assigned in a 1:1 ratio to receive metoprolol, at a target dose of 100 mg daily, in addition to standard care or to receive standard care alone. The primary end point was the time to the first occurrence of a COPD exacerbation, cardiovascular event, or death during 1 year of follow-up.
A total of 1695 patients underwent random assignment; their mean age was 70 years, and 62% were female. The primary end point occurred in 27% of patients assigned to receive metoprolol and in 30% assigned to receive standard care (hazard ratio, 0.87; 95% confidence interval [CI], 0.73 to 1.05; P=0.14). The corresponding hazard ratios were 0.88 (95% CI, 0.72 to 1.06) for COPD exacerbations, 0.73 (95% CI, 0.48 to 1.11) for cardiovascular events, 0.92 (95% CI, 0.48 to 1.77) for death, and 0.87 (95% CI, 0.58 to 1.28) for exacerbations requiring hospitalization. Serious adverse events occurred in 80 (9.4%) of 848 participants in the metoprolol group and 66 (7.8%) of 847 participants in the standard care group. Nonserious adverse events occurred in 293 (34.6%) of 848 patients in the metoprolol group and 247 (29.2%) of 847 in the standard care group.
Among patients with COPD and no cardiovascular disease, metoprolol did not significantly improve the time to a composite of exacerbations, cardiovascular events, or death. (Funded by research grants from the Swedish Research Council and others; ClinicalTrials.gov number, NCT03566667.).

PMID:
42701865
Bibliographic data and abstract were imported from PubMed on 06 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.